Rat Anti-Mouse CD44
- Known as:
- Rat Antibody toMouse CD44
- Catalog number:
- 128-10036-1
- Product Quantity:
- 500
- Category:
- -
- Supplier:
- Ray Biotech
- Gene target:
- Rat Anti-Mouse CD44
Related genes to: Rat Anti-Mouse CD44
- Gene:
- CD44 NIH gene
- Name:
- CD44 molecule (Indian blood group)
- Previous symbol:
- MIC4, MDU2, MDU3
- Synonyms:
- IN, MC56, Pgp1, CD44R, HCELL, CSPG8
- Chromosome:
- 11p13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2019-04-23
Related products to: Rat Anti-Mouse CD44
Related articles to: Rat Anti-Mouse CD44
- CD8 (cluster of differentiation 8) T cells contribute to atherosclerosis, but how they affect VSMCs (vascular smooth muscle cells) is unclear. The protective role of CD8 regulatory T cells (Tregs) and in vivo induction strategies also remain undefined. - Source: PubMed
Publication date: 2026/09/09
Gao WentaoHou YangfengLiu JiaxingHo Cheng KiuCheng Alfred Sze-LokWaldmann HermanZhou BinLau James Y WLui Kathy O - The prevalence of allergic diseases is rising worldwide. Desensitizing immunotherapy is currently the only available treatment, but it is often ineffective for certain allergies, underscoring the need for new treatments. This study tested in an Ovalbumin (OVA)-mediated allergy mouse model whether direct allergen targeting to DC subsets can induce desensitization. A Standard desensitization protocol was compared with an antibody-OVA fusion protein targeting the conventional cDC1 or cDC2 subsets via their respective receptors CD205 (CD205-Fp) or DCIR2 (DCIR2-Fp). Allergen targeting to cDC2 provided long-lasting protection for up to 56 days after desensitization with only nanogram doses of allergen, whereas the Standard therapy protected for only 20 days, requiring microgram doses and repeated injections with Alum adjuvant. CD205-Fp showed no protective effect. Blocking IL-10 either before administering DCIR2-Fp or before allergen challenge completely abolished protection. Standard therapy had moderate effects on CD4 T cells, with early expansion of IL-10 Foxp3 T regulatory type-1 cells (Tr1), followed by an increase in both IL-10 and IL-10 Foxp3 regulatory T cells (Foxp3 Treg). DCIR2-Fp therapy initially expanded IL-10 and IL-10 Foxp3 Treg, but these levels returned to baseline. On day 80, we identified Foxp3 CD44 Treg-like CD8 as the primary source of IL-10. Overall, our data suggest that cDC2 allergen targeting in allergic mice offers a potent, long-lasting IL-10-dependent desensitizing effect. - Source: PubMed
Publication date: 2026/08/25
Aintablian ArpaCyran LauraHelal MoutazLehmann Christian H KImdahl FabianGräfenhan TomRiedel AngelaDudziak DianaKerstan AndreasLutz Manfred B - [This retracts the article DOI: 10.3389/fonc.2024.1495349.]. - Source: PubMed
Publication date: 2026/08/24
- [This retracts the article DOI: 10.3389/fonc.2022.860175.]. - Source: PubMed
Publication date: 2026/08/24
- Lutetium-177 has demonstrated clinical success, particularly in neuroendocrine and prostate cancers, but disease recurrence and progression remain frequent. Terbium-161 offers improved therapeutic potential by delivering higher localized radiation doses. We have previously demonstrated preclinical efficacy of the CD44v6-targeted radiopharmaceutical [Lu]Lu-AKIR001, which is currently under clinical investigation for multiple malignancies (NCT06639191). The present study explored the terbium-161-labeled analogue preclinically, focusing on pancreatic ductal adenocarcinoma, with early proof-of-concept investigations in squamous cell carcinoma, both being highly aggressive and treatment-resistant malignancies. - Source: PubMed
Publication date: 2026/08/24
Gustafsson AmandaMortensen Anja Charlotte LundgrenRondahl VeronicaXu TianqiBratteby KlasBernhardt PeterNestor Marika